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ARTICLE
Rapid aneuploidy detection or karyotyping? Ethical
reflection
Antina de Jong*,1, Wybo J Dondorp2, Daniëlle RM Timmermans3, Jan MM van Lith4 and
Guido MWR de Wert2
No consensus exists whether women at increased risk for trisomy 21, 13, and 18 should be offered stand-alone rapid
aneuploidy detection (RAD) or karyotyping. In this paper, the ethical implications of a fast, relatively cheap and targeted RAD
are examined. The advantages of RAD seem less robust than its proponents suggest. Fast test results only give a short-term
psychological benefit. The cost advantage of RAD is apparent, but must be weighed against consequences like missed
abnormalities, which are evaluated differently by professionals and pregnant women. Since pre-test information about RAD will
have to include telling women about karyotyping as a possible alternative, the advantage of RAD in terms of the quantity of
information that needs to be given may also be smaller than suggested. We conclude that none of the supposed arguments in
favour of RAD is decisive in itself. Whether the case for RAD may still be regarded as convincing when taking these arguments
together seems to depend on one’s implicit view of what prenatal screening is about. Are we basically dealing with a test for
trisomy 21 and a few conditions more? Or are there good grounds for also testing for the wider range of abnormalities that
karyotyping can detect? As professionals and pregnant women may have different views about this, we suggest that the best
approach is to offer women a choice between RAD and karyotyping. This approach is most in line with the general aim of
prenatal screening: providing opportunities for autonomous reproductive choice.
European Journal of Human Genetics (2011) 19, 1020–1025; doi:10.1038/ejhg.2011.82; published online 1 June 2011
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INTRODUCTION
Prenatal screening strategies for chromosomal abnormalities consist of
two steps.1,2 First, a risk assessment for the most common trisomies
(21 and generally also 13 and 18) is carried out. This is based on a
combination of maternal serum testing and fetal nuchal translucency
measurement.3 Second, a diagnostic test is offered to women found to
be at an increased risk of having a child with one of those trisomies.
The diagnosis (usually karyotyping) is performed on fetal material
obtained through either chorionic villus sampling (CVS; at 11–14
weeks’ gestation) or amniocentesis (at 15–18 weeks’ gestation). These
are invasive tests that hold a small but significant risk (0.3–1.0%) of
iatrogenic miscarriage.4,5 Karyotyping has been the gold standard for
prenatal diagnostic testing for nearly half a century. It has a high
reliability in diagnosing numeric chromosome aberrations, as well as
(major) structural abnormalities. These include unbalanced transloca-
tions, balanced translocations (familial and de novo), mosaicism,
supernumerary chromosomes, triploidy, and sex chromosome
abnormalities. Down’s syndrome (trisomy 21) is the most common
aneuploidy causing intellectual and developmental disability.6 Other
chromosomal abnormalities are less frequent and highly variable.
Some of those are lethal (eg, trisomy 13 and trisomy 18), others are
asymptomatic, relatively mild (eg, XXY (Klinefelter’s syndrome), XXX,
XYY), or are of uncertain clinical significance.7,8
Karyotyping is a labour intensive and thus a rather expensive
technique, which takes an average time of 14 days before the test
results can be reported. As karyotyping reveals all chromosomal
abnormalities that can be microscopically detected, it may lead to
other findings than the aneuploidies targeted in prenatal screening.
Among those ‘incidental’ (or with a misnomer: ‘unexpected’) findings,
there can be severe but also mild abnormalities or abnormalities of
which the impact on the health of the child is unsure.7,9–11 The
development of techniques for rapid aneuploidy detection (RAD)
allows cheaper and rapid diagnosis of some selected chromosomal
anomalies. A ‘narrow’ RAD targets the chromosomes 21, 13, and 18,
whereas a ‘broad’ RAD also includes the sex chromosomes. This
development has led to an increased discussion as to whether a full
karyotype is always indicated. RAD has already been introduced in
several countries, but the question whether and if so, how, RAD
should be offered is still under debate.7,8,11–14 Four prenatal diagnostic
test options for women at increased risk can be distinguished:
karyotyping as stand-alone; RAD with subsequent karyotyping;15,16
offering women a choice between RAD and karyotyping14,17,18 and a
stand-alone RAD. Because a stand-alone RAD has been recommended
by the UK National Screening Committee and several individual
commentators,11,19,20 the discussion in this paper focuses on this
approach. We will do so by exploring the main arguments in favour of
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RAD as stand-alone that can be found in the literature: (a) RAD
detects the most important abnormalities; (b) RAD enables fast test
results and reduces anxiety; (c) RAD is cheaper than karyotyping;
(d) the limited scope of RAD simplifies pre-test counselling and
enables adequate informed consent; (e) RAD produces only clear
test results and eases post-test counselling and decision-making; and
(f) RAD guarantees a consistent scope of testing throughout the
screening strategy. Although these arguments may appear to be only
‘technical’, they actually are morally charged arguments as well.
Therefore, an ethical reflection is needed. The insights gained will
be of use to professionals and policymakers in deciding what prenatal
diagnostic test offer is to be preferred in the screening context.
NORMATIVE FRAMEWORK FOR PRENATAL SCREENING
To clarify the perspective of our reflection, we first briefly address the
normative framework for prenatal screening. This framework is based
on the four central principles of health-care ethics. First, the principle
of respect for autonomy not only requires that the woman concerned
should give her adequate informed consent for screening but is also at
the basis of the classical account of the aim of prenatal screening.
There is a strong consensus, at least in Western countries, that prenatal
screening for fetal abnormalities should have the purpose of facilitat-
ing autonomous reproductive choice for pregnant women and their
partners.20,21 The alternative aim of maximising the prevention of the
birth of children with congenital abnormalities is regarded as morally
problematic for two reasons. It not only sends the implied message
that persons with the relevant handicaps are not welcome in society,
but it may also lead to pressure upon pregnant women to undergo
screening and decide to abort in the case of a fetal abnormality. That
would run counter to the principle of autonomy.
Second, the twin principles of beneficence and non-maleficence
require that the benefits to pregnant women from participating should
clearly outweigh the disadvantages that all screening programmes do
have. Finally, the principle of justice requires equality of access and
cost-effective use of financial means, especially when programmes are
collectively or publicly funded.4,22,23
ARGUMENTS IN FAVOUR OF RAD AS STAND-ALONE: AN
EVALUATION
RAD detects the most important abnormalities
The debate about RAD and karyotyping is very much about the scope
of prenatal testing. Although both diagnostic tests are offered as a
follow-up to screening for a fairly limited set of abnormalities, RAD
leads to narrowing the range of possible findings as compared with
karyotyping. In the debate about this, karyotyping is often presented
as the obvious reference point, meaning that the onus of justification
rests with those arguing in favour of more limited testing.24 The
incidence of clinically relevant abnormalities missed by RAD is
estimated to be 1:1000–1:1659, whereas missed abnormalities of
mild or uncertain clinical significance are more frequent.7,14,19 Pro-
ponents of RAD estimate these residual risks to be of limited
relevance.25,26 This is however not obvious, because both the quantity
and quality (or seriousness) of chromosomal abnormalities missed by
RAD can be evaluated differently. A difference in appreciation already
manifests itself in the decision to offer either a ‘broad’ or a ‘narrow’
RAD, which respectively identifies or misses the X and Y chromo-
somes. The clinical significance of sex chromosomal abnormalities is
not always clear and may vary from a relatively mild to an asympto-
matic phenotype. An example is XYY, which has been associated with
intellectual and behavioural problems but does often not actually lead
to any problems at all. To avoid complex pre-test counselling about
the possible outcome of findings of limited or uncertain clinical
significance and to spare women difficult decisions based on such
findings, some professionals want to avoid detecting sex chromosomal
abnormalities. Others find it important not to miss them, just to offer
parents maximum information and maximum autonomy.27
Both a broad and a narrow RAD miss clinically relevant and unclear
autosomal abnormalities that karyotyping does identify. A recent
study including 24 prenatal experts suggests that professionals largely
prefer to detect abnormalities with severe consequences and would
rather not detect chromosomal abnormalities without clinical con-
sequences.28 Dissensus exists with regard to abnormalities with mild
or uncertain outcomes. Interestingly, neither RAD nor karyotyping
corresponds with these wishes of professionals, because RAD covers
only some of the more severe abnormalities, while karyotyping also
detects abnormalities without clinical consequences.28 Proponents of
RAD seem to value the fact that it misses abnormalities as ‘acceptable,
in view of their limited or uncertain clinical relevance’,25 whereas
proponents of karyotyping favour access to these findings because they
have potential (ranging from uncertain to major) clinical significance.7
Pregnant women themselves have different attitudes towards these
findings as well. This is shown by their preference for either RAD or
karyotyping12,14,29 and by the different reproductive choices they
make in case of test results with uncertain clinical significance: most
decide to continue with the pregnancy, but some decide for abortion.7
Different views have been found in the general public and between
countries as well.30,31 In short, no consensus exists about the relevance
of the abnormalities missed by RAD.
A preference for a narrow RAD, a broad RAD, or karyotyping
reflects various views on what delineation of the scope of diagnostic
testing is most in line with facilitating autonomous reproductive
choice as the aim of prenatal screening.
Fast test results
A second reason to prefer RAD is that it generates test results within
1–4 days. This is considerably faster than karyotyping, which takes
Z14 days in Europe, although results can be ready as early as from
7 days in the United States.8 This reduced waiting time for RAD is
clearly advantageous, if it diminishes anxiety for women.19,31,32 Still,
three qualifying remarks need to be made.
First, the striking contrast between the speed of karyotyping in the
United States and Europe in itself bears moral relevance. The differ-
ence between fast (7 days) and slow (21 days) karyotyping is 2 weeks.
This substantial difference raises the question whether RAD is the only
way to shorten the lengthy waiting period that is indeed hard to justify
in view of maternal anxiety, the time left for decision making, and the
emotional burden of (later) termination of the pregnancy. Further-
more, the difference between fast karyotyping (7 days) and a slow
RAD (4 days) is only 3 days, which diminishes the advantage of
reduced maternal anxiety that a choice for RAD would entail. The
absence of a substantial extra waiting time for more comprehensive
information may also motivate women to choose a broad test instead
of a narrow test.29
Second, in the face of the existing rather large difference in
reporting time between karyotyping and RAD, the consequences of
a fast or slow test result should be accounted for. Waiting for test
results of karyotyping can place a significant emotional burden on
women and their partners,26,31 but studies also suggest that RAD has
no overall psychological benefit compared with karyotyping despite
reduced anxiety and stress in the short term.33,34 Moreover, a recent
study, including 103 pregnant women considering amniocentesis,
suggests that anxiety and length of waiting time have some effect on
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women’s preferences, but that the clinical consequences of detected
abnormalities appear to have the greatest influence on the test that
these women would choose.12
Third, part of the clinically relevant abnormalities missed by RAD
will be found by the routine ultrasound scan that most pregnant
women undergo in the second trimester.35,36 If so, test results will
be delayed by 2–10 weeks, compared with, respectively, a late amnio-
centesis and an early CVS. This leaves little time for the emotionally
burdening decision about continuing or terminating the pregnancy, as
abortion is legally prohibited after 20–24 weeks of gestation in many
countries. In case of adverse findings that could have been detected
earlier, it will be difficult for professionals to explain that they chose a
rapid but limited test for the sake of the woman’s well-being.
Restricting and postponing autonomous choice for this reason is
clearly paternalistic. Besides, there is an inconsistency in saying that
findings not detected by RAD are of limited value while at the same
time presenting the later ultrasound scan as a safety net where at least
part of the missed abnormalities will still be found.
To conclude, the ability to produce test results within only a few
days counts in favour of RAD, but this advantage is not unchallenged
and does not seem to provide a decisive reason to offer a stand-alone
RAD.
Financial costs
In the third place, RAD is favoured because it is relatively cheap to
perform. Expenses per trisomy 21 case detected (‘detection/cost’ ratio)
are less for RAD when compared with karyotyping.31,37 Furthermore,
a recent study suggests that both short- and long-term costs, including
incremental cost for a live-born child having a chromosomal abnorm-
ality missed by a broad RAD, are lower for a stand-alone RAD than for
standard karyotyping.12 According to the same study, allowing women
a choice between karyotyping and RAD reduces costs compared with
standard karyotyping. If confirmed in further research, these data
would seem to suggest that, from a purely economic perspective, a
stand-alone RAD is the preferred diagnostic test. Of course, financial
considerations are relevant in the ethical assessment of what test to
offer. It is a requirement of distributive justice that publicly or
collectively funded programmes for prenatal screening should be
cost-effective. But that does not amount to saying that the least costly
option is always the best choice. Even though it should be acknowl-
edged that budgetary constraints may in practice limit the range of
alternative tests available, the challenge is indeed to offer the test that
best serves the aim of prenatal screening, while being proportional in
the sense that the costs involved can be justified from a health-care
economic point of view.
Pre-test counselling: informed consent
Proponents of RAD assert that the limited amount of abnormalities
targeted by RAD ensures that prospective parents can be better
informed about the test and that adequate informed consent can be
obtained more easily. To inform prospective parents about karyo-
typing is more complicated, because this test may also generate a
much wider range of findings, including abnormalities of which the
clinical significance is limited or unclear.11,38 A real concern is
indeed that an offer of karyotyping is not always preceded by
adequate counselling and informed consent and may therefore lead
to outcomes that are ‘unexpected’. Not, of course, for the professional,
but for the woman and her partner who were not informed before-
hand about the possibility of such outcomes. RAD would avoid this.
Still, ‘easy’ pre-test counselling for RAD may be challenged by two
factors.
First, a narrow RAD includes the chromosomes 21, 13, and 18, and
a broad RAD the chromosomes X and Y as well. This means that
proper counselling and informed consent for RAD can still not be
limited to Down’s syndrome, but will also have to include the
differences between trisomies 21, 13, and 18 and the sex chromosomal
abnormalities. In order to enable deliberate choices based on sufficient
and relevant information and consistent with the decision maker’s
values,39 pre-test counselling requires an adequate amount of infor-
mation, adjusted to the patient’s knowledge and capabilities.40 In the
context of RAD, a distinction can be made between three categories of
abnormalities: (1) lethal conditions (trisomies 13 and 18); (2) serious
conditions implying lifelong intensive (medical) aid (Down’s
syndrome); and (3) conditions implying hardly any infirmities
(most sex chromosomal abnormalities). A narrow RAD may detect
abnormalities of categories (1) and (2), whereas a broad RAD will also
find category (3) abnormalities. Karyotyping can detect the same
categories of abnormalities, but will also lead to (4) abnormal findings
of which the clinical implications are unknown. Given this overlap in
types of abnormalities possibly detected by RAD and karyotyping, the
pre-test counselling advantage of RAD may be limited, at least where a
broad RAD is concerned.
Second, it is reasonable to assume that at least some pregnant
women are well acquainted with karyotyping, which has for decades
been the accepted diagnostic test. To prevent that women agree to a
test on the basis of false assumptions, information about the more
limited scope of RAD as compared with karyotyping should be
available. An important aspect of women’s decision making that will
also have to be addressed is their views about whether the narrow
focus of RAD provides sufficient justification for undergoing risky
invasive testing.41,42 Because RAD thus requires more extensive
counselling than generally accounted for by its proponents, the pre-
test counselling advantage of RAD compared with karytoyping may be
less than is often assumed.
The different views on RAD suggest an underlying controversy on
the interpretation of reproductive autonomy and on how pregnant
women’s autonomy could best be served. Should the emphasis be on
optimising and easing the process of decision making for them, or on
maximising the amount of information and reproductive options that
they will be provided with? With regard to decision making, a pro-
RAD assumption would be that information related to karyotyping is
too complicated. However, research among pregnant women has
shown that they differ in their preference for either a limited or
more extensive amount of information.38,43 The challenge will be to
adapt the information accordingly, while ensuring it is not too much
but yet enough information to facilitate adequate informed consent.
To restrain information and to limit choices, based on evaluations by
professionals, may indeed make counselling more easy, but these
evaluations do not necessarily correspond with those of future parents
themselves.
From a moral point of view, the question is which approach is most
in line with the principles underlying the normative framework. On
the one hand, it can be argued that restricting the scope of diagnostic
testing violates the principle of respect for autonomy and falls short of
the requirement of beneficence. On the other hand, respect for
autonomy need not mean that pregnant women should be provided
with as much information about the fetus as possible, as that might
have the adverse effect of undermining rather than furthering their
ability of making autonomous choices and perhaps even lead to
harming the women in question. Indeed, more choice is not necessa-
rily better than less. But the question here is about restricting the scope
of testing prior to any evidence that women would otherwise be
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burdened with information that they cannot handle. Pregnant women
are found to have different information needs regarding the health of
the fetus and also tend to evaluate the features of RAD differently.12,14
It is therefore not evident that the balance of benefits and burdens is
more favourable in case of a stand-alone RAD as compared with
karyotyping.
Post-test counselling: burden of choice and anxiety
Another contended advantage is that by avoiding findings of limited
and unclear clinical significance, RAD does not confront prospective
parents with difficult and unwanted reproductive choices.25,38 Some
professionals are especially uneasy about reporting unclear or mild
abnormalities, because of the dilemmas stemming from it.7 Where test
results are ambivalent or uncertain, prospective parents will have to
decide whether to terminate a wanted pregnancy while the chances of
having a healthy child are quite large, or to continue the pregnancy
with the implication of continued worries even until after the child’s
birth, through its childhood or further. Therefore, some conclude that
generating these findings is not always in the best interest of the
woman or the couple.11,44
However, pregnant women also show interest in findings with
clinically mild consequences and in practice some choose to terminate
a pregnancy in case of unclear or mild findings, as they cannot accept
the uncertainty of the clinical outcome.7,12 Although the possibility of
an ‘unnecessary abortion’ is a burdening prospect for both profes-
sionals and pregnant women, the potential benefit of information
about the fetus possibly being affected should be accounted for as well.
Clearly, decisions regarding testing and termination of pregnancy
should explicitly be left to pregnant women’s own views and values
in order to respect their autonomous reproductive decision making.
The argument that RAD avoids difficult decisions with regard to
terminating or continuing the pregnancy, does not apply to a broad
RAD, which also includes X and Y. To target these abnormalities
undermines this purpose and supposed advantage of RAD, because
most of the sex chromosomal abnormalities are associated with a
relatively mild or asymptomatic phenotype, thus being exactly the
findings that RAD intends to avoid.
The logic of the prenatal screening strategy
In prenatal screening strategies, a positive risk assessment for trisomy
21 (13 and 18) generally functions as the ‘gateway’ to subsequent
diagnostic testing. Because RAD targets these same abnormalities, the
screening strategy itself remains consistent in scope throughout its
subsequent steps. For this reason, RAD is argued to be the most
adequate diagnostic test: test what you screen for. However, to really
avoid any breach in this ‘logic of the screening strategy’, RAD should
only target those abnormalities for which screening is offered in the
first place. If pregnant women are offered prenatal screening for
trisomies 21, 13, and 18, the thrust of the argument would be that
subsequent testing should not also include X and Y.13 Or, for that
matter, RAD should only include trisomy 21 if women are offered
screening for Down’s syndrome only.
An as yet overlooked consequence of standard karyotyping is that it
implies unequal access to diagnostic testing. Pregnant women at an
increased risk for trisomies 21, 13, and 18 are given the possibility of
having the fetus tested for a range of other abnormalities as well,
whereas testing for those ‘further’ abnormalities is unavailable for
other pregnant women.
Are we to conclude that in order to end this inequality, justice
requires a choice between either offering a narrow RAD to the
increased risk group, or offering karyotyping to all pregnant women
(as is the case in the United States)?16 Not necessarily. Although the
inequality in access may be unfortunate, it is not unfair. Both RAD
and karyotyping are performed on fetal material obtained by risky
invasive procedures, although this may change within the years to
come as soon as non-invasive prenatal diagnostic techniques become
widely available.45,46
Until then the miscarriage risk adhered to current invasive proce-
dures has to be reckoned with, which raises the issue of proportion-
ality. Central to this assessment is the detection/miscarriage ratio.
Since women in the group with an increased risk for the few
conditions screened for will already be offered invasive testing for
RAD, this ratio will become more favourable for them if karyotyping
is performed. This ratio will a priori be less favourable for pregnant
women without an increased risk for those conditions. Furthermore,
the principles of non-maleficence and respect for autonomy are at
stake when women are denied the possibility of getting additional
information from fetal material obtained through a procedure with a
miscarriage risk.13,47 For this reason, some argue in favour of further
expanding the range of abnormalities to be included in diagnostic
testing offered to those having CVS or amniocentesis in the context of
prenatal screening, for example, by including relatively common
heritable diseases like cystic fibrosis and hemoglobinopathies.11 How-
ever, the problem of unequal access will make itself even more clearly
felt when such a broader test is offered only to those with a positive
test for a limited number of chromosomal abnormalities.
Although unequal access to the ‘surplus’ findings of karyotyping
may not be a decisive reason to offer a stand-alone RAD, it does
constitute a moral reason to reconsider current access to karyotyping.
CONCLUSION
There is no consensus whether women at increased risk for trisomy 21
(13 and 18) should be offered RAD or karyotyping. RAD has some
advantageous features: it is fast, relatively cheap, and produces clear
test results. Assessment of these aspects, however, shows that the
advantages ascribed to RAD are not conclusive. Fast test results have a
short term but not an overall psychological benefit over later results.
Therefore, the time gain is of minor importance when weighing a fast
but limited test (RAD) against a slower but more extensive test
(karyotyping). The relevance of abnormalities missed by RAD are
evaluated differently between and among professionals and women,
and the counselling advantages due to the targeted scope of RAD in
the pre-test and post-test situation are relative. RAD is cheaper than
karyotyping, but this cannot settle the issue.
We conclude that, from a moral point of view, the case for RAD is
less strong than it may at first seem. It is not immediately obvious that
RAD is more in line with the requirement of respect for autonomy
than karyotyping. Nor is it clear that the balance of advantages and
disadvantages is more favourable for the women concerned in the case
of RAD. Neither does the fact that women with a prior risk for
common aneuploidies are offered wider testing to which others have
no access amount to a serious injustice. However, even if a separate
assessment of the alleged advantages of RAD does not show any of
them to be decisive, it can still be asked whether their cumulative effect
might not decide the argument in favour of RAD. The answer to this
will depend mainly on what one thinks the scope of prenatal screening
and testing should be. The moral framework of prenatal screening
itself is not decisive in this regard. For those who think that testing for
trisomy 21 or perhaps for common aneuploidies is what prenatal
screening is really about, the arguments for limiting the test offer to a
narrow or broader RAD may sound convincing. However, others may
find that there are good grounds for wanting prenatal screening to at
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least include the wider range of conditions that karyotyping might
detect. Given that there is no objective perspective from whence to
decide between these views, leaving the choice to the women
concerned would at least have the benefit of being in line with the
general aim of offering opportunities for autonomous reproductive
choice.
This approach would also have the more practical advantage of
being open towards future debates that are most likely about broad-
ening rather than limiting the scope of prenatal screening. The
dynamics of the field points in the opposite direction from that
proposed by those arguing for RAD. New techniques that can identify
an even broader scope of heterogeneous abnormalities than karyotyp-
ing are already on the horizon.48,49 Broader diagnostic testing may
even become possible on cell-free fetal DNA that is present in the
plasma of pregnant women.45 Apart from the advantage of allowing
testing early in pregnancy and without the miscarriage risk adhered to
current invasive techniques, the possibility of broad non-invasive
diagnostic testing raises further ethical issues.50 Without wanting to
pre-empt the debate about whether these developments should lead to
further broadening the scope of prenatal screening, we suggest that
offering RAD as a stand-alone sends the wrong message. Is protecting
pregnant women from difficult choices the best way of preparing for
the challenges ahead? Instead of assuming that anything beyond RAD
is too difficult for them, it may be better to invest in finding
approaches to counselling and informed consent that are adjusted
to broader kinds of testing without compromising central moral
principles.
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